Reference entry · Dual GLP-1/glucagon receptor agonist
Mazdutide
Also known as: IBI362 · GLP-1/glucagon dual agonist
- Class
- Dual GLP-1/glucagon receptor agonist
- Primary targets (literature)
- GLP-1 receptor, glucagon receptor
- Regulatory context
- Investigational — not FDA-approved. High catalog-interest development compound with variable COA quality.
Overview
Mazdutide is a dual GLP-1 and glucagon receptor agonist in active clinical development, studied in obesity and type 2 diabetes research programs. Evidence maturity is earlier than for semaglutide or tirzepatide.
Mechanism in research literature
Dual receptor engagement combines incretin-mediated glucose and satiety biology with glucagon-pathway energy-expenditure hypotheses studied in phase 2 trials.
Common research focus areas
- Phase 2 obesity and T2D dose-ranging literature
- Dual-agonist comparison with retatrutide and survodutide
- Development-stage evidence vs. approved GLP-1 drugs
- Modified peptide identity and acylation analytics
Full literature roundup
Read the cited research summary
A dual GLP-1 and glucagon receptor agonist in active clinical development. What published phase 2 literature reports within an RUO frame.
Mazdutide research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.